Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 56 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Diagnostic, Supportive care, Treatment				Active				40 to 65				Other				2004/949 NCT00111241


2.		Aromatase Inhibitor Clinical Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				40 to 70				NIGMS				0412-14 UO1-GM61373-06, NCT00228956


3.		Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				CFEM345C2403 NCT00171847


4.		Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				50 and over				Pharmaceutical / Industry				CFEM345DUS59 NCT00688909


5.		Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				Postmenopausal				Pharmaceutical / Industry				CZOL446GDE19 NCT00375752


6.		Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				not specified				Other				N07MAN Eudract 2007-007030-20, NCT00684216


7.		Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				65 and over				Other				0120070323 NCT00698971

Last Modified: 1/14/2009 First Published: 1/1/1998


8.		Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Postmenopausal				NCI, Pharmaceutical / Industry				CAN-NCIC-MA17 CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17

Last Modified: 6/12/2008 First Published: 5/28/2004


9.		Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				GSK-EGF30008 UCLA-0311034-01, NCT00073528


10.		Assessing Impact of Loco-Regional Treatment on Survival in Metastatic Breast Cancer at Presentation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 to 65				Other				TMH/153/2004 NCT00193778

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute